Baxter International (BAX)
NYSE:BAX
Want to see BAX full AI Analyst Report?
BAX Stock Chart & Stats
$18.71
$0.05(0.17%)
At close: 4:00 PM EST
$18.71
$0.05(0.17%)
Day’s Range― - ―
52-Week Range$15.73 - $32.68
Previous CloseN/A
Volume899.70K
Average Volume (3M)8.24M
Market Cap
$8.88B
Enterprise Value$16.25B
Total Cash (Recent Filing)$2.02B
Total Debt (Recent Filing)$9.69B
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Jul 23, 2026EPS Estimate
0.37Next Dividend Ex-DateN/A
Dividend Yield2.75%
Share Statistics
EPS (TTM)-2.10
Shares Outstanding516,252,500
10 Day Avg. Volume6,340,326
30 Day Avg. Volume8,244,482
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)1.60
Price to Sales (P/S)0.87
P/FCF Ratio30.35
Enterprise Value/Market Cap1.83
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit4.77
Enterprise Value/Ebitda21.84
Forecast
1Y Price Target
$20.09Price Target Upside7.38% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)1.91
Revenue Forecast (FY)$11.36B
Bulls Say, Bears Say
Bulls Say
Operational Improvement In Key UnitsOperational improvements in Advanced Surgery, Care & Connectivity Solutions and Drug Compounding bolster growth prospects and could support margin recovery under management's transformation initiatives.
Revenue OutperformanceSales exceeded analyst expectations across all business segments, with international strength and broad top-line resilience supporting upside to revenue consensus if momentum continues.
Valuation GapThe stock trades at a notable discount to peer averages, creating potential upside if execution on revenue growth and margin improvement materializes.
Bears Say
Credit Outlook And Cash Flow RiskS&P's move to a Negative credit outlook highlights leverage and free cash flow requirements, and inclusion of obligations like leases and pension shortfalls makes leverage appear higher unless cash generation improves.
Product Shipment DisruptionA ship hold and related uncertainty for the Novum IQ infusion pump program reduced pump shipments and left customers awaiting clarity, limiting near-term pump revenue.
Profitability Pressure From Mix And CostsUnfavorable product mix, inventory adjustments and higher tax expense weakened gross and operating margins, creating near-term pressure on reported profitability.
Baxter International News
BAX FAQ
What was Baxter International’s price range in the past 12 months?
Baxter International lowest stock price was $15.73 and its highest was $32.68 in the past 12 months.
What is Baxter International’s market cap?
Baxter International’s market cap is $8.88B.
When is Baxter International’s upcoming earnings report date?
Baxter International’s upcoming earnings report date is Jul 23, 2026 which is in 79 days.
How were Baxter International’s earnings last quarter?
Baxter International released its earnings results on Apr 30, 2026. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.311 by $0.059.
Is Baxter International overvalued?
According to Wall Street analysts Baxter International’s price is currently Undervalued.
Does Baxter International pay dividends?
Baxter International pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 2.75%. See more information on Baxter International dividends here
What is Baxter International’s EPS estimate?
Baxter International’s EPS estimate is 0.37.
How many shares outstanding does Baxter International have?
Baxter International has 516,252,500 shares outstanding.
What happened to Baxter International’s price movement after its last earnings report?
Baxter International reported an EPS of $0.37 in its last earnings report, beating expectations of $0.311. Following the earnings report the stock price went up 4.024%.
Which hedge fund is a major shareholder of Baxter International?
Currently, no hedge funds are holding shares in BAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Baxter International Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.09 (7.38% Upside)
$20.09 (7.38% Upside)
Blogger Sentiment
Bullish
BAX Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 15.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.35%
12-Months-Change
Fundamentals
Return on Equity
-13.78%
Trailing 12-Months
Asset Growth
-6.84%
Trailing 12-Months
Company Description
Baxter International
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
BAX Company Deck
BAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced notable operational progress (product launches, improved cash flow, continuous improvement adoption and backorder remediation) and a reiterated full-year framework against meaningful near-term financial headwinds (35% EPS decline, margin compression, Novum shipment hold and supply constraints in injectables). Management emphasized a clear turnaround plan, debt reduction priority and expected second-half recovery, but the first-half results and ongoing risks temper optimism.View all BAX earnings summariesBAX Net sales Breakdown
47.13% Medical Products and Therapies
27.31% Healthcare Systems and Technologies
22.17% Pharmaceuticals
3.39% Other
BAX Stock 12 Month Forecast
Average Price Target
$20.09
▲(7.38% Upside)
Technical Analysis
Ownership Overview
0.38% Insiders
35.55% Mutual Funds
17.22% Other Institutional Investors
21.10% Public Companies and
Individual Investors